Skip to main content

Is My Product Recalled?

Food Recalls Medication Recalls Baby Products Pet Products Toys Electronics Household Vehicles Medical Devices Other

Scan How It Works Saved Get Alerts

Menu

Search All Recalls Latest Recalls Scan Barcode Get Alerts

Categories

Food Recalls Medication Recalls Baby Products Pet Products Toys Electronics Household Vehicles Medical Devices Other

Resources

How Recalls Work FAQ Recall Classifications Statistics & Trends About

Your Recalls

Loading...

Stay Informed

Get email alerts when new recalls match your interests.

Recall data is updated hourly from official government sources. Very recent recalls may not yet appear. About our data sources

About

We make U.S. recall data searchable and accessible for consumers and businesses.

Site

FAQ
Browse by State
Statistics
Recall Classifications
About
Enterprise API

Legal

Privacy Policy
Terms of Service
Report Incorrect Info

Official Sources

FDA Recalls ↗
USDA FSIS ↗
CPSC Recalls ↗
NHTSA Recalls ↗

Home
/
Brands
/
Akorn, Inc.

Akorn, Inc. Recalls

All product recalls associated with Akorn, Inc..

Get alerts for this brand

Recall Summary

Total Recalls

1000

Past Year

730

Class I (Serious)

175

Most Recent

Jan 2026

Data from FDA, USDA, CPSC, and NHTSA public records. Recall counts vary by company size, industry, and reporting practices. Always check official sources for current information.

Showing 1821–1840 of 11124 recalls

Moxifloxacin HCl Ophthalmic Solution (Akorn) – Stability Studies Discontinued (2023)

CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Class IIModerate

FDAApr 26, 2023Nationwide• Akorn, Inc.

Olopatadine HCl Ophthalmic Solution (Akorn) – Stability Study Halt (2023)

CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Class IIModerate

FDAApr 26, 2023Nationwide• Akorn, Inc.

Proparacaine HCl Ophthalmic Solution (Akorn) – Stability Studies Discontinued (2023)

CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Class IIModerate

FDAApr 26, 2023Nationwide• Akorn, Inc.

Lidocaine Ointment (Akorn) – CGMP Deviation (2023)

CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Class IIModerate

FDAApr 26, 2023Nationwide• Akorn, Inc.

Clobetasol Propionate Ointment (Akorn) – Stability Study Halt (2023)

CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Class IIModerate

FDAApr 26, 2023Nationwide• Akorn, Inc.

Olopatadine HCl Ophthalmic Solution (Akorn) – Stability Studies Discontinued (2023)

CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Class IIModerate

FDAApr 26, 2023Nationwide• Akorn, Inc.

Vitamin D Supplement Drops (Akorn) – Stability Studies Discontinued (2023)

CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Class IIModerate

FDAApr 26, 2023Nationwide• Akorn, Inc.

Cromolyn Sodium Ophthalmic Solution (Akorn) – Stability Study Halt (2023)

CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Class IIModerate

FDAApr 26, 2023Nationwide• Akorn, Inc.

Acyclovir Oral Suspension (Akorn) – Stability Studies Discontinued (2023)

CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Class IIModerate

FDAApr 26, 2023Nationwide• Akorn, Inc.

Lidocaine HCl Jelly (Akorn) – Stability Studies Discontinued (2023)

CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Class IIModerate

FDAApr 26, 2023Nationwide• Akorn, Inc.

Lorazepam Oral Concentrate (Akorn) – Stability Studies Discontinued (2023)

CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Class IIModerate

FDAApr 26, 2023Nationwide• Akorn, Inc.

Valproic Acid Oral Solution (Akorn) – Stability Studies Discontinued (2023)

CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Class IIModerate

FDAApr 26, 2023Nationwide• Akorn, Inc.

Acetaminophen & Codeine Oral Solution (Akorn) – Stability Studies Discontinued (2023)

CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Class IIModerate

FDAApr 26, 2023Nationwide• Akorn, Inc.

Tobramycin Ophthalmic Solution (Akorn) – Stability Studies Discontinued (2023)

CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Class IIModerate

FDAApr 26, 2023Nationwide• Akorn, Inc.

Calcitriol Injection (Akorn) – Stability Studies Discontinued (2023)

CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Class IIModerate

FDAApr 26, 2023Nationwide• Akorn, Inc.

Lactulose Solution (Akorn) – Stability Studies Discontinued (2023)

CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Class IIModerate

FDAApr 26, 2023Nationwide• Akorn, Inc.

Acetic Acid Otic Solution (Akorn) – Stability Studies Discontinued (2023)

CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Class IIModerate

FDAApr 26, 2023Nationwide• Akorn, Inc.

Apraclonidine Ophthalmic Solution (Akorn) – Stability Studies Discontinued (2023)

CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Class IIModerate

FDAApr 26, 2023Nationwide• Akorn, Inc.

Midazolam Injection (Akorn) – Stability Studies Discontinued (2023)

CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Class IIModerate

FDAApr 26, 2023Nationwide• Akorn, Inc.

Tropicamide Ophthalmic Solution (Akorn) – Stability Studies Discontinued (2023)

CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Class IIModerate

FDAApr 26, 2023Nationwide• Akorn, Inc.

1...90 919293 94...557

Page 92 of 557Next